Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

PROTAC therapy as a new targeted therapy for lung cancer

Molecular Therapy(2022)10.1016/j.ymthe.2022.11.011Source: DataRank Database

PROTAC therapy as a new targeted therapy for lung cancer is a research paper published in Molecular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 83 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access83 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.78)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Guangrong Zheng ORCID,Frederic J. Kaye ORCID,Lizi Wu ORCID,Jennifer W. Li

Live enrichment

PubMed:36415148 PMC:PMC10014230 OpenAlex:https://openalex.org/W4309761367

NIH

Grant: R01CA234351

NIH

Grant: R01DE023641

National Institutes of Health

Grant: 2R01DE023641-05A1

Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland

National Institutes of Health

Grant: 5R01CA234351-05

Aberrant CRTC activation as a unique vulnerability of lung cancer with LKB1 inactivation

University of Florida Health

FWCI

5.78

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10014230/pdf/main.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525001622006694?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001622006694?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10014230

Fields of Study

Protein Degradation and InhibitorsPeptidase Inhibition and AnalysisUbiquitin and proteasome pathways0301 basic medicine0303 health sciences03 medical and health sciencesHumansProteasome Endopeptidase ComplexProteinsProteolysisUbiquitin-Protein LigasesLung Neoplasms

MeSH Terms

HumansLung NeoplasmsProteinsUbiquitin-Protein LigasesProteasome Endopeptidase ComplexProteolysis

Keywords

Lung cancerTargeted therapyUbiquitin ligaseCancerMedicineProtein degradationCancer researchTreatment of lung cancerDrug discoveryProteasomeUbiquitinDrug developmentBioinformaticsPharmacologyBiologyDrugOncologyInternal medicineCell biologyBiochemistryProtacsProteolysis Targeting ChimerasArgeted Protein DegradationProteasome Endopeptidase ComplexLung NeoplasmsUbiquitin-Protein LigasesProteolysisHumansProteinsReview

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being